Product Reports Resources Pricing Login Book a demo
COMPANY PROFILE

Ruizhen Regenerative Medicine Technology

Request full access

Advancing personalized regenerative medicine with iPSC technology

ChinaFounded 2019Biotech & Life Sciences

About Ruizhen Regenerative Medicine Technology

Guangzhou Ruizhen Regenerative Medicine Technology Co., Ltd., operating as Regen Therapeutics, is a biopharmaceutical firm established in January 2019 by a team of scientists in Guangzhou. The company focuses on the clinical translation of regenerative medicine, with a core emphasis on induced pluripotent stem cell (iPSC) technology. The legal representative, Chairman, and General Manager is Zhang Ling.

The company's operations are vertically integrated, encompassing research, production, and sales aimed at clinical stem cell therapy, drug development, and personalized precision medicine. Regen Therapeutics has established a comprehensive technology platform that covers the entire iPSC cell therapy process, including iPSC reprogramming and cell banking, differentiation techniques for immune and nerve cells, and gene modification for creating engineered iPS cell lines. This infrastructure is housed within a 2,500-square-meter GMP-grade cell production and R&D center, capable of meeting cell demands through Phase II clinical trials and storing thousands of standardized stem cell resources. A key milestone for the company was receiving the first patent authorization in China for its independently developed technology for differentiating dopamine precursor cells, which has shown promising therapeutic effects in primate models of Parkinson's disease.

Regen Therapeutics pursues a dual business model. It provides one-stop research services to pharmaceutical companies, medical institutions, and scientific research organizations, offering iPSC reprogramming and storage, iPSC-derived functional cells, and the production of exosomes and organoids. Concurrently, the company develops its own proprietary pipeline of universal, off-the-shelf cell therapy products derived from iPSCs for treating oncological and neurological disorders. Key pipelines include iDA-001 for Parkinson's disease, iNK001, a natural killer cell line for tumor immunotherapy, and an iMSN pipeline targeting the rare Huntington's disease. In May 2025, the company secured nearly CNY 100 million in a Pre-A financing round to advance these pipelines, particularly to support the IND application and investigator-initiated trials (IIT) for its Parkinson's treatment.

Source: Dealroom company data

At a glance

Status
Operational
Open positions
None listed
Dealroom signal
16.0/100
Industry
Health
Sub-industry
BioTechnology
Sector
Biotechnology, Precision Medicine, Disease, Biotech and Pharma, Rare Diseases, DT and LS, science-based
Links
Website

Funding history

1 recorded event

Company financing events and reported valuations.

Deal typeDateAmountValuationInvestorsSource
SEED✓Equity / VC May 2025 $14M $55M Canton Venture Capital ↗
Showing the latest 1 of 1 recorded eventsBook a demo for the full funding history →

Investments and acquisitions

Capital deployed

Recent portfolio relationships for companies that also act as investors or acquirers.

Ruizhen Regenerative Medicine Technology in its local ecosystem

Live from Dealroom

The Ruizhen Regenerative Medicine Technology office with the hot startups, most funded companies and investors around it. Hover or tap a pin.

Loading the map…

Dealroom maps whole ecosystems like this one for cities, regions and governments. See the ecosystem platform →

Investors

1 investor on the cap table

From Dealroom's funding and investor records, grouped by the round each investor first entered.

Seed1 investor entered at this stage

  • Canton Venture Capital
Founders Hidden — book a demo/100 quality score
Key operators Hidden — book a demo quality score
Potential founders Hidden — book a demo likely future founders
Startup mafia Hidden — book a demo alumni-founded startups
Talent movements Hidden — book a demo in · Hidden — book a demo out past 12 months

Source: Dealroom Talent Intelligence.

Global footprint

Workforce and web traffic by country
Workforce by country
🇨🇳 China HQ
Book a demo for the full country breakdown

Market sentiment

Posts on X, past 7 days

An AI-synthesised read of the highest-engagement posts about Ruizhen Regenerative Medicine Technology on X, ranked by likes and reposts, corporate channels excluded.

Reading the room on X — pulling top posts and synthesizing themes…

Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour

See Ruizhen Regenerative Medicine Technology’s full profile on Dealroom

Request a free trial to see the complete deal history, financials, people graph and growth signals.

Takes under a minute. Already use Dealroom? Log in.